These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34845368)

  • 1. Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis.
    Furtado VF; Brauneis D; Weinberg J; Elhassan N; Sloan JM; Sanchorawala V
    Bone Marrow Transplant; 2022 Feb; 57(2):306-308. PubMed ID: 34845368
    [No Abstract]   [Full Text] [Related]  

  • 2. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
    Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A
    Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076
    [No Abstract]   [Full Text] [Related]  

  • 5. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
    Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
    Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
    Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
    Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).
    Chaulagain CP; Herlitz LC; Fu J; Bilani N; Lucitt C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e826-e831. PubMed ID: 32703752
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.
    Browning S; Quillen K; Sloan JM; Doros G; Sarosiek S; Sanchorawala V
    Blood; 2017 Sep; 130(11):1383-1386. PubMed ID: 28698204
    [No Abstract]   [Full Text] [Related]  

  • 10. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
    Sanchorawala V
    Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.
    Bal S; Estrada-Merly N; Costa LJ; Qazilbash MH; Kumar S; D'Souza A
    Blood Cancer J; 2023 Nov; 13(1):170. PubMed ID: 37968258
    [No Abstract]   [Full Text] [Related]  

  • 12. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.
    D'Souza A; Huang J; Hari P
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):768-770. PubMed ID: 26743343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
    Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
    Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
    Vaxman I; Dispenzieri A
    Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Hassan H; Verma K; Ferri G; Brauneis D; Quillen K; Sloan JM; Sanchorawala V; Edwards CV
    Transplant Cell Ther; 2022 Nov; 28(11):761.e1-761.e7. PubMed ID: 35970300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; Honhar M; Varma A; Cornelison AM; Rondon G; Parmar S; Shah ND; Bashir Q; Hosing C; Popat U; Weber DM; Thomas S; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2197-2203. PubMed ID: 30016656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy.
    Mellgard GS; Bhutani D; Mapara MY; Maurer MS; Radhakrishnan J; Lentzsch S; Chakraborty R
    Bone Marrow Transplant; 2024 Aug; 59(8):1181-1183. PubMed ID: 38724598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.